Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced it has been selected to participate in an ERA-Net-funded applied pathogenomics project, which is using systems biology to identify the role of small non-coding RNA (sncRNA) in infectious diseases. The sncRNAomics European Research Consortium is identifying novel targets for diagnostics and therapy of five major high-risk gram-positive human microbial pathogens. The Genedata Phylosopher biological data management solution was chosen as the central management and infrastructure platform for sharing and interpreting the experimental data, in particular the next-generation sequencing and tiling array data generated within the consortium.
“We chose to partner with Genedata because they have a successful track record in transcriptome-based biomarker identification and also because they have the strongest product portfolio for centralized data management for target validation,” explained Dr. Torsten Hain of the University of Giessen (Germany) and sncRNAomics Project Coordinator. “In health care, and especially in a clinical environment, microbial resistance increases exponentially. Antibiotics have become a blunt sword and we need new approaches in diagnostics and therapy,” continued Dr. Hain. “Small non-coding RNAs in bacteria are an emerging class of new gene expression regulators, but their role in colonization and pathogenicity is largely unknown. Within this interdisciplinary project we are applying for the first time a systems biology approach on major human pathogens to elucidate the role of sncRNAs, and to identify and validate new sncRNA-based diagnostic biomarkers and drug targets.
Genedata Phylosopher will integrate all experimental data from the pathogens and the host organisms. Using a genome-wide scale and regulatory network approach, the consortium will adapt high-throughput technologies such as transcriptomics by tiling arrays as well as next-generation sequencing technologies to identify novel sncRNAs and to investigate their role in regulation. Genedata Phylosopher supports the reconstruction of disease pathways, in particular the refinement of functional assignment of genes, transcripts, proteins, regulatory motifs, RNAs and their molecular interactions, to regulatory networks during host-pathogen interactions
"We are delighted to have this international and interdisciplinary consortium choose Genedata as their central data management and analysis infrastructure,” said Dr. Othmar Pfannes, CEO of Genedata. “This partnership further demonstrates Genedata’s leadership in delivering scalable and flexible research IT infrastructure solutions for target validation, drug development, and biomarker discovery, even for novel target classes such as sncRNAs.”
About sncRNAomics European Research Consortium
Novel anti-infectives are of high priority for global health care and sncRNAs in bacteria are an emerging class of new gene expression regulators, but their role in colonization and pathogenicity in largely unknown. The consortium brings together seven research groups from three countries to combine novel high-throughput sncRNA screening methods, whole-genome transcriptomics and proteomics and bioinformatics. These methods will be coupled with molecular characterization to provide new data regarding sncRNAs in major high-risk Grampositive microbes (e.g. Staphylococcus, Streptococcus, Enterococcus, Clostridium, and Listeria). Potential new drugs and diagnostic biomarkers will be validated using tissue culture and subsequently in in-vivo models. The sncRNAomics project is granted under the frame of the second multinational ERA-Net PathoGenoMics call. For more information, please visit www.pathogenomics-era.net/2ndJointCall
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com
Marketing & Communications
Phone: +41 61 511 8459
Phone: +1 508 881 3109
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.